Cargando…

Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report

BACKGROUND: Overexpression of human epidermal growth factor receptor 2 (HER2) is associated with aggressive disease and poor prognosis. Traditional HER2-targeted agents can improve clinical outcome and have played an essential role in therapy. Pyrotinib is a newly irreversible tyrosine kinase inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Lina, Zhang, Fengchun, Ma, Yue, Zuo, Li, Xu, Yingchun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468538/
https://www.ncbi.nlm.nih.gov/pubmed/32943881
http://dx.doi.org/10.2147/OTT.S252117
_version_ 1783578240540999680
author He, Lina
Zhang, Fengchun
Ma, Yue
Zuo, Li
Xu, Yingchun
author_facet He, Lina
Zhang, Fengchun
Ma, Yue
Zuo, Li
Xu, Yingchun
author_sort He, Lina
collection PubMed
description BACKGROUND: Overexpression of human epidermal growth factor receptor 2 (HER2) is associated with aggressive disease and poor prognosis. Traditional HER2-targeted agents can improve clinical outcome and have played an essential role in therapy. Pyrotinib is a newly irreversible tyrosine kinase inhibitor (TKI) that is well developed for the treatment of HER2-positive advanced breast tumors. CASE PRESENTATION: A 37-year-old postpartum female was presented at a local hospital and was diagnosed with HER2-positive stage IIIB (cT4N1M0) invasive micropapillary adenocarcinoma in the left breast with left axillary metastatic lymph nodes. The patient failed to respond to two cycles of the doxorubicin plus cyclophosphamide (AC) regimen but achieved clinical partial response (cPR) after 4 cycles of the combination of pyrotinib, trastuzumab, paclitaxel and cisplatin (PTPC) regimen according to radiologic assessments. Then, she underwent left-side modified radical mastectomy (MRM) and achieved pathologic complete response (pCR), as confirmed by postoperative pathology. The patient held on receiving 2 cycles of the targeted therapy plus chemotherapy with trastuzumab, paclitaxel plus cisplatin (TPC) and adjuvant radiation therapy but continued to receive targeted therapy with trastuzumab and pertuzumab during the 1-year follow-up period. There has been no clinical evidence of disease progression so far. CONCLUSION: Breast cancer overexpressing HER2 is a malignant tumor responsible for many cancer-related deaths. The combination of pyrotinib plus other targeted chemotherapy can dramatically improve the outcome of locally advanced disease.
format Online
Article
Text
id pubmed-7468538
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-74685382020-09-16 Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report He, Lina Zhang, Fengchun Ma, Yue Zuo, Li Xu, Yingchun Onco Targets Ther Case Report BACKGROUND: Overexpression of human epidermal growth factor receptor 2 (HER2) is associated with aggressive disease and poor prognosis. Traditional HER2-targeted agents can improve clinical outcome and have played an essential role in therapy. Pyrotinib is a newly irreversible tyrosine kinase inhibitor (TKI) that is well developed for the treatment of HER2-positive advanced breast tumors. CASE PRESENTATION: A 37-year-old postpartum female was presented at a local hospital and was diagnosed with HER2-positive stage IIIB (cT4N1M0) invasive micropapillary adenocarcinoma in the left breast with left axillary metastatic lymph nodes. The patient failed to respond to two cycles of the doxorubicin plus cyclophosphamide (AC) regimen but achieved clinical partial response (cPR) after 4 cycles of the combination of pyrotinib, trastuzumab, paclitaxel and cisplatin (PTPC) regimen according to radiologic assessments. Then, she underwent left-side modified radical mastectomy (MRM) and achieved pathologic complete response (pCR), as confirmed by postoperative pathology. The patient held on receiving 2 cycles of the targeted therapy plus chemotherapy with trastuzumab, paclitaxel plus cisplatin (TPC) and adjuvant radiation therapy but continued to receive targeted therapy with trastuzumab and pertuzumab during the 1-year follow-up period. There has been no clinical evidence of disease progression so far. CONCLUSION: Breast cancer overexpressing HER2 is a malignant tumor responsible for many cancer-related deaths. The combination of pyrotinib plus other targeted chemotherapy can dramatically improve the outcome of locally advanced disease. Dove 2020-08-27 /pmc/articles/PMC7468538/ /pubmed/32943881 http://dx.doi.org/10.2147/OTT.S252117 Text en © 2020 He et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
He, Lina
Zhang, Fengchun
Ma, Yue
Zuo, Li
Xu, Yingchun
Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report
title Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report
title_full Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report
title_fullStr Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report
title_full_unstemmed Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report
title_short Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report
title_sort pathological complete response from pyrotinib combined with trastuzumab, paclitaxel and cisplatin in a postpartum woman with her2-positive locally advanced breast cancer: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468538/
https://www.ncbi.nlm.nih.gov/pubmed/32943881
http://dx.doi.org/10.2147/OTT.S252117
work_keys_str_mv AT helina pathologicalcompleteresponsefrompyrotinibcombinedwithtrastuzumabpaclitaxelandcisplatininapostpartumwomanwithher2positivelocallyadvancedbreastcanceracasereport
AT zhangfengchun pathologicalcompleteresponsefrompyrotinibcombinedwithtrastuzumabpaclitaxelandcisplatininapostpartumwomanwithher2positivelocallyadvancedbreastcanceracasereport
AT mayue pathologicalcompleteresponsefrompyrotinibcombinedwithtrastuzumabpaclitaxelandcisplatininapostpartumwomanwithher2positivelocallyadvancedbreastcanceracasereport
AT zuoli pathologicalcompleteresponsefrompyrotinibcombinedwithtrastuzumabpaclitaxelandcisplatininapostpartumwomanwithher2positivelocallyadvancedbreastcanceracasereport
AT xuyingchun pathologicalcompleteresponsefrompyrotinibcombinedwithtrastuzumabpaclitaxelandcisplatininapostpartumwomanwithher2positivelocallyadvancedbreastcanceracasereport